CN102008628B - 用于治疗女性生殖道病毒感染的药物及其缓释制剂的制备方法 - Google Patents
用于治疗女性生殖道病毒感染的药物及其缓释制剂的制备方法 Download PDFInfo
- Publication number
- CN102008628B CN102008628B CN200910190118.4A CN200910190118A CN102008628B CN 102008628 B CN102008628 B CN 102008628B CN 200910190118 A CN200910190118 A CN 200910190118A CN 102008628 B CN102008628 B CN 102008628B
- Authority
- CN
- China
- Prior art keywords
- genital tract
- female genital
- medicine
- parts
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 81
- 238000002360 preparation method Methods 0.000 title claims abstract description 40
- 210000005002 female reproductive tract Anatomy 0.000 title claims abstract description 33
- 230000009385 viral infection Effects 0.000 title claims abstract description 32
- 239000003405 delayed action preparation Substances 0.000 title abstract 4
- 239000000284 extract Substances 0.000 claims abstract description 66
- 239000002994 raw material Substances 0.000 claims abstract description 37
- 239000010231 banlangen Substances 0.000 claims abstract description 27
- 239000007787 solid Substances 0.000 claims abstract description 26
- 239000003223 protective agent Substances 0.000 claims abstract description 25
- 230000000840 anti-viral effect Effects 0.000 claims abstract description 17
- 230000000975 bioactive effect Effects 0.000 claims abstract description 10
- 239000000126 substance Substances 0.000 claims abstract description 10
- 229940069521 aloe extract Drugs 0.000 claims abstract description 9
- 239000000203 mixture Substances 0.000 claims description 47
- 229920001282 polysaccharide Polymers 0.000 claims description 31
- 239000005017 polysaccharide Substances 0.000 claims description 31
- 208000036142 Viral infection Diseases 0.000 claims description 28
- 150000004676 glycans Chemical class 0.000 claims description 27
- 108700028325 pokeweed antiviral Proteins 0.000 claims description 20
- 239000003795 chemical substances by application Substances 0.000 claims description 19
- -1 Carrageenan polysaccharide Chemical class 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- 239000000679 carrageenan Substances 0.000 claims description 15
- 229920001525 carrageenan Polymers 0.000 claims description 15
- 229940113118 carrageenan Drugs 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 15
- 235000010418 carrageenan Nutrition 0.000 claims description 14
- 239000011149 active material Substances 0.000 claims description 13
- 239000013543 active substance Substances 0.000 claims description 13
- 239000002904 solvent Substances 0.000 claims description 13
- 230000001900 immune effect Effects 0.000 claims description 12
- 230000036039 immunity Effects 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 12
- 238000001291 vacuum drying Methods 0.000 claims description 12
- 239000000499 gel Substances 0.000 claims description 11
- 229920002521 macromolecule Polymers 0.000 claims description 11
- 230000036961 partial effect Effects 0.000 claims description 11
- 230000001954 sterilising effect Effects 0.000 claims description 11
- 238000004659 sterilization and disinfection Methods 0.000 claims description 11
- 229940006091 aloe polysaccharide Drugs 0.000 claims description 10
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 10
- 241000206575 Chondrus crispus Species 0.000 claims description 9
- 239000002202 Polyethylene glycol Substances 0.000 claims description 9
- 239000006166 lysate Substances 0.000 claims description 9
- 229920001223 polyethylene glycol Polymers 0.000 claims description 9
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 8
- 229920001353 Dextrin Polymers 0.000 claims description 8
- 239000004375 Dextrin Substances 0.000 claims description 8
- 229920001503 Glucan Polymers 0.000 claims description 8
- 235000019425 dextrin Nutrition 0.000 claims description 8
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 8
- 239000000600 sorbitol Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 7
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 7
- 229930195725 Mannitol Natural products 0.000 claims description 7
- 239000000594 mannitol Substances 0.000 claims description 7
- 235000010355 mannitol Nutrition 0.000 claims description 7
- 239000002562 thickening agent Substances 0.000 claims description 7
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 6
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 6
- 239000008101 lactose Substances 0.000 claims description 6
- 239000000829 suppository Substances 0.000 claims description 6
- 240000002045 Guettarda speciosa Species 0.000 claims description 5
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 5
- 229920001491 Lentinan Polymers 0.000 claims description 5
- 102000008300 Mutant Proteins Human genes 0.000 claims description 5
- 108010021466 Mutant Proteins Proteins 0.000 claims description 5
- 229920002125 Sokalan® Polymers 0.000 claims description 5
- 229920002000 Xyloglucan Polymers 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 5
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 5
- 229940115286 lentinan Drugs 0.000 claims description 5
- 235000010987 pectin Nutrition 0.000 claims description 5
- 239000001814 pectin Substances 0.000 claims description 5
- 229920001277 pectin Polymers 0.000 claims description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 4
- 241001061264 Astragalus Species 0.000 claims description 4
- 229920000148 Polycarbophil calcium Polymers 0.000 claims description 4
- 235000006533 astragalus Nutrition 0.000 claims description 4
- 229960001631 carbomer Drugs 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 210000004233 talus Anatomy 0.000 claims description 4
- 235000013311 vegetables Nutrition 0.000 claims description 4
- 229920001285 xanthan gum Polymers 0.000 claims description 4
- 235000010493 xanthan gum Nutrition 0.000 claims description 4
- 239000000230 xanthan gum Substances 0.000 claims description 4
- 229940082509 xanthan gum Drugs 0.000 claims description 4
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 3
- 241001147468 Chondrus ocellatus Species 0.000 claims description 3
- 229920002907 Guar gum Polymers 0.000 claims description 3
- 235000010489 acacia gum Nutrition 0.000 claims description 3
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 3
- 229940072056 alginate Drugs 0.000 claims description 3
- 235000010443 alginic acid Nutrition 0.000 claims description 3
- 229920000615 alginic acid Polymers 0.000 claims description 3
- 230000003103 anti-anaerobic effect Effects 0.000 claims description 3
- 239000003429 antifungal agent Substances 0.000 claims description 3
- 239000003899 bactericide agent Substances 0.000 claims description 3
- 239000000665 guar gum Substances 0.000 claims description 3
- 235000010417 guar gum Nutrition 0.000 claims description 3
- 229960002154 guar gum Drugs 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 229960000292 pectin Drugs 0.000 claims description 3
- 229950005134 polycarbophil Drugs 0.000 claims description 3
- 239000002423 protozoacide Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 241000459479 Capsula Species 0.000 claims description 2
- 101000959794 Homo sapiens Interferon alpha-2 Proteins 0.000 claims description 2
- 241001597008 Nomeidae Species 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims description 2
- 229940040145 liniment Drugs 0.000 claims description 2
- 239000000865 liniment Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 241000700605 Viruses Species 0.000 abstract description 27
- 230000000694 effects Effects 0.000 abstract description 27
- 239000000463 material Substances 0.000 abstract description 7
- 210000004877 mucosa Anatomy 0.000 abstract description 7
- 241000219357 Cactaceae Species 0.000 abstract description 3
- 230000002500 effect on skin Effects 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 241001116389 Aloe Species 0.000 description 33
- 235000011399 aloe vera Nutrition 0.000 description 32
- 239000008187 granular material Substances 0.000 description 19
- 241000701806 Human papillomavirus Species 0.000 description 18
- 238000000605 extraction Methods 0.000 description 18
- 229940079593 drug Drugs 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 15
- 206010046914 Vaginal infection Diseases 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 241000700584 Simplexvirus Species 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 10
- 210000001215 vagina Anatomy 0.000 description 10
- 201000008100 Vaginitis Diseases 0.000 description 9
- 206010008323 cervicitis Diseases 0.000 description 8
- 230000003628 erosive effect Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 206010008342 Cervix carcinoma Diseases 0.000 description 7
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 7
- 208000006374 Uterine Cervicitis Diseases 0.000 description 7
- 201000010881 cervical cancer Diseases 0.000 description 7
- 201000003505 cervical polyp Diseases 0.000 description 7
- 235000010413 sodium alginate Nutrition 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 4
- 206010008263 Cervical dysplasia Diseases 0.000 description 4
- 208000009889 Herpes Simplex Diseases 0.000 description 4
- 241000341655 Human papillomavirus type 16 Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 4
- 208000007951 cervical intraepithelial neoplasia Diseases 0.000 description 4
- 238000002651 drug therapy Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000008176 lyophilized powder Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 238000010298 pulverizing process Methods 0.000 description 4
- 239000000661 sodium alginate Substances 0.000 description 4
- 229940005550 sodium alginate Drugs 0.000 description 4
- 210000003501 vero cell Anatomy 0.000 description 4
- AFHJQYHRLPMKHU-XXWVOBANSA-N Aloin Natural products O=C1c2c(O)cc(CO)cc2[C@H]([C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O2)c2c1c(O)ccc2 AFHJQYHRLPMKHU-XXWVOBANSA-N 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 3
- 206010018404 Glucagonoma Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- CPUHNROBVJNNPW-UHFFFAOYSA-N aloin A Natural products OC1C(O)C(O)C(CO)OC1OC1C2=CC(CO)=CC(O)=C2C(=O)C2=C(O)C=CC=C21 CPUHNROBVJNNPW-UHFFFAOYSA-N 0.000 description 3
- AFHJQYHRLPMKHU-WEZNYRQKSA-N aloin B Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@H]1C2=CC(CO)=CC(O)=C2C(=O)C2=C(O)C=CC=C21 AFHJQYHRLPMKHU-WEZNYRQKSA-N 0.000 description 3
- 230000037444 atrophy Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- AFHJQYHRLPMKHU-UHFFFAOYSA-N isobarbaloin Natural products OC1C(O)C(O)C(CO)OC1C1C2=CC(CO)=CC(O)=C2C(=O)C2=C(O)C=CC=C21 AFHJQYHRLPMKHU-UHFFFAOYSA-N 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 239000000575 pesticide Substances 0.000 description 3
- 238000000053 physical method Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000005909 tumor killing Effects 0.000 description 3
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- YDQWDHRMZQUTBA-UHFFFAOYSA-N Aloe emodin Chemical compound C1=CC=C2C(=O)C3=CC(CO)=CC(O)=C3C(=O)C2=C1O YDQWDHRMZQUTBA-UHFFFAOYSA-N 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 241000606153 Chlamydia trachomatis Species 0.000 description 2
- 208000031404 Chromosome Aberrations Diseases 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000037062 Polyps Diseases 0.000 description 2
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 description 2
- 229960004150 aciclovir Drugs 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000002155 anti-virotic effect Effects 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940038705 chlamydia trachomatis Drugs 0.000 description 2
- 229960002152 chlorhexidine acetate Drugs 0.000 description 2
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 2
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 2
- 231100000005 chromosome aberration Toxicity 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 229960002509 miconazole Drugs 0.000 description 2
- 231100000299 mutagenicity Toxicity 0.000 description 2
- 230000007886 mutagenicity Effects 0.000 description 2
- 230000005305 organ development Effects 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 210000003200 peritoneal cavity Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- MCSINKKTEDDPNK-UHFFFAOYSA-N propyl propionate Chemical compound CCCOC(=O)CC MCSINKKTEDDPNK-UHFFFAOYSA-N 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 210000005000 reproductive tract Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229960005053 tinidazole Drugs 0.000 description 2
- 230000005760 tumorsuppression Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
- 108020005097 23S Ribosomal RNA Proteins 0.000 description 1
- 244000144927 Aloe barbadensis Species 0.000 description 1
- 235000002961 Aloe barbadensis Nutrition 0.000 description 1
- 244000101643 Aloe ferox Species 0.000 description 1
- 235000015858 Aloe ferox Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010015108 Epstein-Barr virus infection Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 241000150562 Hantaan orthohantavirus Species 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000032982 Hemorrhagic Fever with Renal Syndrome Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 240000000950 Hippophae rhamnoides Species 0.000 description 1
- 235000003145 Hippophae rhamnoides Nutrition 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 241000334160 Isatis Species 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 241000304370 Orostachys Species 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 239000010103 Podophyllin Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- 206010040840 Skin erosion Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 108010047265 aloctin A Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003622 anti-hsv Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 108700004675 bleomycetin Proteins 0.000 description 1
- QYOAUOAXCQAEMW-UTXKDXHTSA-N bleomycin A5 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCNCCCCN)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QYOAUOAXCQAEMW-UTXKDXHTSA-N 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 201000003988 chronic cervicitis Diseases 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 229960003913 econazole Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 231100000025 genetic toxicology Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000012943 hotmelt Substances 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 230000004987 nonapoptotic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229940068582 podophyllin Drugs 0.000 description 1
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 238000010181 skin prick test Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 208000014221 sudden cardiac arrest Diseases 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000009804 total hysterectomy Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000033041 viral attachment to host cell Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
类型 | 总例数 | 治愈 | 显效 | 有效 | 无效 | 治愈率 | 有效率 | 副作用 |
阴道炎 | 81 | 73 | 2 | 4 | 2 | 90% | 98% | 无 |
宫颈炎 | 100 | 86 | 3 | 7 | 4 | 86% | 96% | 无 |
宫颈息肉 | 65 | 58 | 1 | 5 | 1 | 90% | 99% | 无 |
HPV阳性 | 59 | 54 | 1 | 4 | 0 | 91% | 100% | 无 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200910190118.4A CN102008628B (zh) | 2009-09-08 | 2009-09-08 | 用于治疗女性生殖道病毒感染的药物及其缓释制剂的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200910190118.4A CN102008628B (zh) | 2009-09-08 | 2009-09-08 | 用于治疗女性生殖道病毒感染的药物及其缓释制剂的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102008628A CN102008628A (zh) | 2011-04-13 |
CN102008628B true CN102008628B (zh) | 2014-04-09 |
Family
ID=43839091
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200910190118.4A Active CN102008628B (zh) | 2009-09-08 | 2009-09-08 | 用于治疗女性生殖道病毒感染的药物及其缓释制剂的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102008628B (zh) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103816089A (zh) * | 2014-03-11 | 2014-05-28 | 广州市洋林生物科技开发有限公司 | 一种皮肤粘膜抗菌液及皮肤粘膜抗菌湿巾 |
CN104353058B (zh) * | 2014-10-14 | 2016-12-07 | 海南森瑞谱生命科学药业股份有限公司 | 商陆抗病毒蛋白冻干粉复合剂及其制备方法 |
CN105326807A (zh) * | 2015-11-20 | 2016-02-17 | 上海华新生物高技术有限公司 | 一种干扰素阴道泡腾胶囊及其制备方法 |
CN106109542A (zh) * | 2016-07-29 | 2016-11-16 | 桂林淮安天然保健品开发有限公司 | 可阻断巨细胞病毒在母婴之间传递的药物组合物及其制备方法 |
CN105998142A (zh) * | 2016-07-29 | 2016-10-12 | 桂林淮安天然保健品开发有限公司 | 抗巨细胞病毒的药物组合物及其制备方法 |
CN106580791B (zh) * | 2016-12-23 | 2020-06-09 | 广州睿森生物科技有限公司 | 一种抗菌组合物和私处护理产品 |
CN107325178A (zh) * | 2017-06-29 | 2017-11-07 | 佛山市南海区普罗圣塔生物科技有限公司 | 一种抗人巨细胞病毒卵黄抗体及其制备方法和应用 |
CN108514640A (zh) * | 2018-05-11 | 2018-09-11 | 江苏森瑞谱生物制药有限公司 | 含商陆抗病毒蛋白和免疫活性物质的药物组合物及其用途 |
CN109276703A (zh) * | 2018-11-06 | 2019-01-29 | 海南森瑞谱生命科学药业股份有限公司 | 植物抗病毒蛋白复合剂及其制备方法 |
CN110507816A (zh) * | 2019-09-20 | 2019-11-29 | 江西善行生物科技有限公司 | 一种用于清除hpv的复合制剂 |
CN113057996A (zh) * | 2021-04-02 | 2021-07-02 | 正青春祛痘祛斑美容(杭州)有限公司 | 一种女性缩阴润滑凝胶及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1366783B1 (en) * | 2002-05-28 | 2006-04-05 | CHEN, Bih Cheng | Medicinal herbal preparation for disinfecting vaginas |
CN101099735A (zh) * | 2007-07-24 | 2008-01-09 | 艾硕特生物科技(昆明)有限公司 | 一种广谱、高效的微生物杀灭剂 |
CN101164583A (zh) * | 2006-10-16 | 2008-04-23 | 海南森瑞谱生命科学药业股份有限公司 | 治疗上皮糜烂的复合制剂及其制备方法 |
-
2009
- 2009-09-08 CN CN200910190118.4A patent/CN102008628B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1366783B1 (en) * | 2002-05-28 | 2006-04-05 | CHEN, Bih Cheng | Medicinal herbal preparation for disinfecting vaginas |
CN101164583A (zh) * | 2006-10-16 | 2008-04-23 | 海南森瑞谱生命科学药业股份有限公司 | 治疗上皮糜烂的复合制剂及其制备方法 |
CN101099735A (zh) * | 2007-07-24 | 2008-01-09 | 艾硕特生物科技(昆明)有限公司 | 一种广谱、高效的微生物杀灭剂 |
Also Published As
Publication number | Publication date |
---|---|
CN102008628A (zh) | 2011-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102008628B (zh) | 用于治疗女性生殖道病毒感染的药物及其缓释制剂的制备方法 | |
CN101254212B (zh) | 美洲大蠊提取物有效部位在制备治疗生殖器疱疹药物中的应用 | |
CN101164583B (zh) | 治疗上皮糜烂的复合制剂及其制备方法 | |
CA2985862C (en) | Application of ginseng extracts, ginsenoside and ginsenoside derivatives in preparation of medicines or health products for treating cytomegalovirus infection disorders | |
CN107961265A (zh) | 一种预防及抑制hpv病毒的妇科凝胶 | |
WO2020010919A1 (zh) | 一种中药组合物、中药复方制剂及其制备方法和应用 | |
CN106421673A (zh) | 一种治疗hpv病毒感染的中药组合物及其制备方法 | |
CN111700998A (zh) | 复方中成药在治疗新型冠状病毒感染的肺炎covid-19中的应用 | |
CN101683423B (zh) | 一种中药组合物在制备治疗水痘药物中的应用 | |
CN103006773A (zh) | 一种小儿清热宁中药颗粒 | |
CN104784489B (zh) | 一种治疗慢性宫颈炎合并hpv感染的中药制剂 | |
CN111419997A (zh) | 一种治疗尖锐湿疣的中药组合物 | |
CN110292621A (zh) | 抗hpv病毒感染的抗毒抑菌复合剂及其转相凝胶的制备方法 | |
CN116270940B (zh) | 一种防治hpv病毒感染的中药组合物及其制备方法和应用 | |
CN108324924A (zh) | 苦瓜蛋白在制备抗人乳头瘤病毒感染药物中的应用 | |
CN107551174A (zh) | 一种治疗宫颈hpv感染的外用中药及其制备方法 | |
CN102512359B (zh) | 一种具有抗疱疹病毒作用的芒果苷乳膏 | |
CN101607009B (zh) | 一种用于治疗感冒的药物组合物 | |
CN1315480C (zh) | 治疗疱疹病毒的药物组合物及其生产方法 | |
CN103230568B (zh) | 一种小儿贝诺酯维b1颗粒及其制备工艺 | |
CN105878854B (zh) | 一种治疗非淋菌性尿道炎的中药组合物及其制备方法 | |
CN114366786A (zh) | 一种具有软坚散结功效的中药组合物及其制备方法和应用 | |
CN1436565A (zh) | 治疗宫颈糜烂的外用药及其制备方法 | |
CN104622987A (zh) | 一种治疗慢性肝炎肝硬化的药物组合物及应用 | |
CN104524184A (zh) | 一种抗hpv和提高免疫机能的中药冲剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: HAINAN SENRUIPU LIFE SCIENCE MEDICINE STOCK CO., L Free format text: FORMER OWNER: SHENZHEN LONGYANG BIOLOGY TECHNOLOGIES CO., LTD. Effective date: 20140107 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 518000 SHENZHEN, GUANGDONG PROVINCE TO: 570000 HAIKOU, HAINAN PROVINCE |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20140107 Address after: The national high tech Industrial Park in Hainan province Haikou trough road 570000 No. 5 Applicant after: HAINAN SR-BIOPHARMA CO.,LTD. Address before: 518000 Guangdong city of Shenzhen province Nanshan District Taoyuan Lu Bei Chang Xing Lu Chang Xing East Square East apartment room 15N Applicant before: Shenzhen Longyang BIology Technologies Co.,Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: JIANGSU SENRUIPU BIOLOGICAL PHARMACEUTICAL CO., LT Free format text: FORMER OWNER: HAINAN SENRUIPU LIFE SCIENCE MEDICINE STOCK CO., LTD. Effective date: 20140708 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 570000 HAIKOU, HAINAN PROVINCE TO: 225300 TAIZHOU, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20140708 Address after: 225300 Jiangsu city of Taizhou province China medicine Road East Yang Chengkou Road on the north side of G47 building on the west side of the 5 floor Patentee after: JIANGSU SR-BIOPHARMA BIOLOGICAL PHARMACEUTICAL CO.,LTD. Address before: The national high tech Industrial Park in Hainan province Haikou trough road 570000 No. 5 Patentee before: HAINAN SR-BIOPHARMA CO.,LTD. |
|
ASS | Succession or assignment of patent right |
Owner name: HAINAN SENRUIPU LIFE SCIENCE MEDICINE STOCK CO., L Free format text: FORMER OWNER: JIANGSU SENRUIPU BIOLOGICAL PHARMACEUTICAL CO., LTD. Effective date: 20150327 |
|
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 225300 TAIZHOU, JIANGSU PROVINCE TO: 570000 HAIKOU, HAINAN PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20150327 Address after: The national high tech Industrial Park in Hainan province Haikou trough road 570000 No. 5 Patentee after: HAINAN SR-BIOPHARMA CO.,LTD. Address before: 225300 Jiangsu city of Taizhou province China medicine Road East Yang Chengkou Road on the north side of G47 building on the west side of the 5 floor Patentee before: JIANGSU SR-BIOPHARMA BIOLOGICAL PHARMACEUTICAL CO.,LTD. |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160309 Address after: 225300 Jiangsu city of Taizhou province China medicine Road East Yang Chengkou Road on the north side of G47 building on the west side of the 5 floor Patentee after: JIANGSU SR-BIOPHARMA BIOLOGICAL PHARMACEUTICAL CO.,LTD. Address before: The national high tech Industrial Park in Hainan city of Haikou province trough Road No. 5 Patentee before: HAINAN SR-BIOPHARMA CO.,LTD. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210519 Address after: 570000 No.5, Yaogu 1st Road, national high tech Industrial Park, Haikou City, Hainan Province Patentee after: HAINAN SR-BIOPHARMA Co.,Ltd. Address before: 225300 5th floor, west side of g47 building, north side of Xinyang Road, east side of Tai Road, China medicine Chengkou, Qinzhou City, Jiangsu Province Patentee before: JIANGSU SR-BIOPHARMA BIOLOGICAL PHARMACEUTICAL Co.,Ltd. |
|
CP03 | Change of name, title or address |
Address after: No. 5 Yaogu 1st Road, National High tech Industrial Park, Haikou City, Hainan Province, 570311 Patentee after: Senruipu Life Science Pharmaceutical (Hainan) Group Co.,Ltd. Address before: 570000 No.5, Yaogu 1st Road, national high tech Industrial Park, Haikou City, Hainan Province Patentee before: HAINAN SR-BIOPHARMA CO.,LTD. |
|
CP03 | Change of name, title or address |